Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report)'s stock price fell 2% during trading on Thursday . The company traded as low as $0.54 and last traded at $0.55. 1,035,689 shares traded hands during trading, a decline of 1% from the average session volume of 1,049,095 shares. The stock had previously closed at $0.56.
Analysts Set New Price Targets
A number of research firms have recently commented on UNCY. Benchmark reaffirmed a "speculative buy" rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a report on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Unicycive Therapeutics in a report on Wednesday, January 29th.
Check Out Our Latest Stock Report on Unicycive Therapeutics
Unicycive Therapeutics Trading Down 3.7 %
The stock has a market capitalization of $56.36 million, a P/E ratio of -0.56 and a beta of 2.26. The firm's fifty day moving average is $0.62 and its 200-day moving average is $0.54.
Hedge Funds Weigh In On Unicycive Therapeutics
Institutional investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its position in Unicycive Therapeutics by 142.4% in the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares in the last quarter. XTX Topco Ltd acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at about $29,000. Virtu Financial LLC increased its position in Unicycive Therapeutics by 566.8% in the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock valued at $30,000 after acquiring an additional 62,881 shares in the last quarter. Geode Capital Management LLC increased its position in Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. Finally, Acuta Capital Partners LLC acquired a new stake in Unicycive Therapeutics in the 3rd quarter valued at about $807,000. 40.42% of the stock is owned by institutional investors.
Unicycive Therapeutics Company Profile
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Recommended Stories
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
